Vitamin Shoppe (VSI) Receiving Somewhat Favorable Press Coverage, Report Finds

News headlines about Vitamin Shoppe (NYSE:VSI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vitamin Shoppe earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the specialty retailer an impact score of 44.220781897064 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the media headlines that may have effected Accern’s rankings:

Vitamin Shoppe (NYSE:VSI) last issued its quarterly earnings data on Wednesday, August 9th. The specialty retailer reported $0.23 EPS for the quarter, missing the Zacks’ consensus estimate of $0.39 by ($0.16). The company had revenue of $304.84 million for the quarter, compared to analyst estimates of $314.74 million. Vitamin Shoppe had a negative net margin of 11.98% and a positive return on equity of 8.33%. The business’s revenue was down 8.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.55 EPS.

A number of equities research analysts have commented on the company. Zacks Investment Research raised Vitamin Shoppe from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 18th. BidaskClub downgraded Vitamin Shoppe from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Deutsche Bank AG reissued a “hold” rating and issued a $7.00 target price (down previously from $14.00) on shares of Vitamin Shoppe in a report on Thursday, August 10th. Morgan Stanley set a $8.00 target price on Vitamin Shoppe and gave the company a “hold” rating in a report on Thursday, August 10th. Finally, Goldman Sachs Group, Inc. (The) reissued a “sell” rating and issued a $6.00 target price (down previously from $13.00) on shares of Vitamin Shoppe in a report on Thursday, August 10th. Four investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. Vitamin Shoppe presently has an average rating of “Hold” and an average price target of $9.92.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at

In related news, Director John D. Bowlin acquired 40,000 shares of the stock in a transaction dated Friday, August 25th. The shares were acquired at an average price of $5.50 per share, with a total value of $220,000.00. Following the acquisition, the director now owns 56,028 shares in the company, valued at approximately $308,154. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.07% of the company’s stock.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Insider Buying and Selling by Quarter for Vitamin Shoppe (NYSE:VSI)

Insider Buying and Selling by Quarter for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with's FREE daily email newsletter.

Leave a Reply